Nasal Polyps (Nasal Polyposis) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Powered by
All the vital news, analysis, and commentary curated by our industry experts.
Nasal polyps (Nasal polyposis) is an inflammatory condition that develops in the nasal lining of the nose. They are non-cancerous growths. Signs and symptoms include runny nose, postnasal drip, headache, snoring, and loss of sense of taste. Risk factors include asthma, aspirin sensitivity, cystic fibrosis, Churg-Strauss syndrome, and allergic fungal sinusitis. Treatment includes steroid medications.
The Nasal Polyps (Nasal Polyposis) Drugs in Development market research report provides an overview of the Nasal Polyps (Nasal Polyposis) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Nasal Polyps (Nasal Polyposis), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Nasal Polyps (Nasal Polyposis) and features dormant and discontinued projects.
Nasal Polyps Pipeline Drugs Market Targets
The targets of the Nasal Polyps pipeline drugs market are Immunoglobulin E ), Interleukin 5 Receptor Subunit Alpha, Glucocorticoid Receptor, Interleukin 1 Receptor Like 1, Interleukin 33, Interleukin 4 Receptor Subunit Alpha, Interleukin 5, and Prostaglandin D2 Receptor 2.
Nasal Polyps pipeline drugs market, by targets
For more target insights, download a free report sample
Mechanisms of Action of Nasal Polyps Pipeline Drugs Market
The mechanisms of action of the Nasal Polyps pipeline drugs market are Immunoglobulin E Inhibitor, Interleukin 5 Receptor Subunit Alpha Antagonist, Glucocorticoid Receptor Agonist, Interleukin 33 Inhibitor, Interleukin 4 Receptor Subunit Alpha Antagonist, Interleukin 5 Inhibitor, and Prostaglandin D2 Receptor 2 Antagonist.
Nasal Polyps pipeline drugs market, by mechanisms of action
For more mechanisms of action insights, download a free report sample
Routes of Administration in Nasal Polyps Pipeline Drugs Market
The routes of administration in the Nasal Polyps pipeline drugs market are subcutaneous, intravenous, nasal, and oral.
Nasal Polyps pipeline drugs market, by routes of administration
For more routes of administration insights, download a free report sample
Molecule Types in Nasal Polyps Pipeline Drugs Market
The molecule types in the Nasal Polyps pipeline drugs market are monoclonal antibody, small molecule, and biologic.
Nasal Polyps pipeline drugs market, by molecule types
For more molecule type insights, download a free report sample
Key Nasal Polyps Pipeline Drugs Market Companies
Some of the key companies in the Nasal Polyps pipeline drugs market are Kyowa Kirin Co Ltd, AnaptysBio Inc, Curateq Biologics Pvt Ltd, F. Hoffmann-La Roche Ltd, GlaxoSmithKline Plc, Novartis AG, OptiNose Inc, Pfizer Inc, Suzhou Connect Biopharmaceuticals Ltd, and Synermore Biologics Co Ltd.
Nasal Polyps pipeline drugs market, by key companies
To know more about key companies, download a free report sample
Market report overview
Targets | Immunoglobulin E ), Interleukin 5 Receptor Subunit Alpha, Glucocorticoid Receptor, Interleukin 1 Receptor Like 1, Interleukin 33, Interleukin 4 Receptor Subunit Alpha, Interleukin 5, and Prostaglandin D2 Receptor 2 |
Mechanisms of Action | Immunoglobulin E Inhibitor, Interleukin 5 Receptor Subunit Alpha Antagonist, Glucocorticoid Receptor Agonist, Interleukin 33 Inhibitor, Interleukin 4 Receptor Subunit Alpha Antagonist, Interleukin 5 Inhibitor, and Prostaglandin D2 Receptor 2 Antagonist |
Routes of Administration | Subcutaneous, Intravenous, Nasal, and Oral |
Molecule Types | Monoclonal Antibody, Small Molecule, and Biologic |
Key Companies | Kyowa Kirin Co Ltd, AnaptysBio Inc, Curateq Biologics Pvt Ltd, F. Hoffmann-La Roche Ltd, GlaxoSmithKline Plc, Novartis AG, OptiNose Inc, Pfizer Inc, Suzhou Connect Biopharmaceuticals Ltd, and Synermore Biologics Co Ltd |
Scope
This report provides:
- A snapshot of the global therapeutic landscape of Nasal Polyps (Nasal Polyposis) (Ear Nose Throat Disorders).
- Reviews of pipeline therapeutics for Nasal Polyps (Nasal Polyposis) (Ear Nose Throat Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Pipeline products based on several stages of development ranging from pre-registration to discovery and undisclosed stages.
- Descriptive drug profiles for the pipeline products which include product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities.
- Reviews of key companies involved in Nasal Polyps (Nasal Polyposis) (Ear Nose Throat Disorders) therapeutics and enlists all their major and minor projects.
- Evaluation of Nasal Polyps (Nasal Polyposis) (Ear Nose Throat Disorders) targeted therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA), and molecule type.
- All the dormant and discontinued pipeline projects.
- Reviews of the latest news and deals related to pipeline therapeutics for Nasal Polyps (Nasal Polyposis) (Ear Nose Throat Disorders).
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counterstrategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Nasal Polyps (Nasal Polyposis) (Ear Nose Throat Disorders).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Nasal Polyps (Nasal Polyposis) (Ear Nose Throat Disorders) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Curateq Biologics Pvt Ltd
F. Hoffmann-La Roche Ltd
GlaxoSmithKline Plc
Kyowa Kirin Co Ltd
Novartis AG
OptiNose Inc
Pfizer Inc
Suzhou Connect Biopharmaceuticals Ltd
Synermore Biologics Co Ltd
Table of Contents
Table
Figures
Frequently asked questions
-
What are the targets of the Nasal Polyps pipeline drugs market?
The targets of the Nasal Polyps pipeline drugs market are Immunoglobulin E ), Interleukin 5 Receptor Subunit Alpha, Glucocorticoid Receptor, Interleukin 1 Receptor Like 1, Interleukin 33, Interleukin 4 Receptor Subunit Alpha, Interleukin 5, and Prostaglandin D2 Receptor 2.
-
What are the mechanisms of action of the Nasal Polyps pipeline drugs market?
The mechanisms of action of the Nasal Polyps pipeline drugs market are Immunoglobulin E Inhibitor, Interleukin 5 Receptor Subunit Alpha Antagonist, Glucocorticoid Receptor Agonist, Interleukin 33 Inhibitor, Interleukin 4 Receptor Subunit Alpha Antagonist, Interleukin 5 Inhibitor, and Prostaglandin D2 Receptor 2 Antagonist.
-
What are the routes of administration in the Nasal Polyps pipeline drugs market?
The routes of administration in the Nasal Polyps pipeline drugs market are subcutaneous, intravenous, nasal, and oral.
-
What are the molecule types in the Nasal Polyps pipeline drugs market?
The molecule types in the Nasal Polyps pipeline drugs market are monoclonal antibody, small molecule, and biologic.
-
Which are the key companies in the Nasal Polyps pipeline drugs market?
Some of the key companies in the Nasal Polyps pipeline drugs market are Kyowa Kirin Co Ltd, AnaptysBio Inc, Curateq Biologics Pvt Ltd, F. Hoffmann-La Roche Ltd, GlaxoSmithKline Plc, Novartis AG, OptiNose Inc, Pfizer Inc, Suzhou Connect Biopharmaceuticals Ltd, and Synermore Biologics Co Ltd.
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.